Comparative Pharmacology
Head-to-head clinical analysis: CEFAZOLIN versus TAZIDIME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFAZOLIN versus TAZIDIME.
Cefazolin vs TAZIDIME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and disrupting peptidoglycan cross-linking. This leads to cell lysis and death primarily in susceptible gram-positive bacteria.
Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
1-2 g IV/IM every 6-8 hours; maximum 12 g/day.
1 to 2 g IV/IM every 8 hours; maximum 6 g/day.
None Documented
None Documented
1.8 hours in normal renal function; extends to 30–70 hours in end-stage renal disease (CrCl <10 mL/min).
Clinical Note
moderateCefazolin + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Cefazolin."
Clinical Note
moderateCefazolin + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefazolin."
Clinical Note
moderateCeftazidime + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Ceftazidime."
Clinical Note
moderateCefazolin + Picosulfuric acid
1.9 hours (range 1.5-2.8 hours); prolonged in renal impairment (up to 20 hours in ESRD).
Renal: 80–90% unchanged via glomerular filtration and tubular secretion; biliary: <1%; fecal: negligible.
Primarily renal (80-90% unchanged via glomerular filtration), biliary/fecal <5%.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefazolin."